Function-preserving surgery for breast cancer

被引：3

作者：

Inaji H. ^{[1
]}

Egawa C. ^{[1
]}

Komoike Y. ^{[1
]}

Motomura K. ^{[1
]}

Nishiyama K. ^{[2
]}

Kataoka T.R. ^{[3
]}

Koyama H. ^{[1
]}

机构：

[1] Department of Breast Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Prefectural Hospital Organization, Higashinari-ku, Osaka 537-8511

[2] Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Prefectural Hospital Organization, Osaka

[3] Department of Pathology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Prefectural Hospital Organization, Osaka

来源：

International Journal of Clinical Oncology | 2006年 / 11卷 / 5期

关键词：

Breast cancer; Breast-conserving treatment; Ipsilateral breast tumor recurrence; Nonsurgical ablation; Sentinel node biopsy;

D O I：

10.1007/s10147-006-0615-0

中图分类号：

学科分类号：

摘要：

Breast-conserving treatment is well established as a safe method of treatment for the majority of breast cancers. Issues to be addressed concerning breast-conserving treatment include the omission of radiation therapy in low-risk patients, optimal local and systemic treatment for ipsilateral breast tumor recurrence, classification of ipsilateral breast tumor recurrence into true recurrences and new primary cancers, and the selection of patients who are eligible for breast conservation after neoadjuvant chemotherapy. There is much evidence that sentinel node biopsy is an accurate method of screening for axillary nodal status in patients with early breast cancer. Clearly, the avoidance of axillary dissection improves quality of life. The feasibility, accuracy, and timing of sentinel node biopsy in patients undergoing neoadjuvant chemotherapy are not yet clear. Also, the clinical significance of micrometastasis should be evaluated to determine the optimal application of sentinel node biopsy. There is interest in replacing breast-conserving treatment by nonsurgical ablation, although additional findings are needed to show that this technique is a true advance in breast cancer treatment. © 2006 The Japan Society of Clinical Oncology.

引用

页码：344 / 350

页数：6

共 81 条

[1]

Newman L.A., Kuerer H.M., Advances in breast conservation therapy, J Clin Oncol, 23, pp. 1685-1697, (2005)

[2]

Schwartz G.F., Veronesi U., Clough K.B., Proceedings of the Consensus Conference on Breast Conservation, April 28 to May 1, 2005, Milan Italy, Cancer, 107, pp. 242-250, (2006)

[3]

Morrow M., Strom E.A., Bassett L.W., Standard for breast conservation in the management of invasive breast carcinoma, CA Cancer J Clin, 52, pp. 277-300, (2002)

[4]

Veronesi U., Cascinelli N., Mariani L., Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, N Engl J Med, 347, pp. 1227-1232, (2002)

[5]

Fisher B., Anderson S., Bryant J., Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer, N Engl J Med, 17, pp. 1233-1241, (2002)

[6]

Lannin D.R., Haffty B.G., End results of salvage therapy after failure of breast-conservation surgery, Oncology, 18, pp. 272-279, (2004)

[7]

Freedman G.M., Fowble B.L., Local recurrence after mastectomy or breast-conserving surgery and radiation, Oncology, 14, pp. 1561-1581, (2000)

[8]

Results of questionnaires concerning breast cancer surgery in Japan 1980-2003, Breast Cancer, 12, pp. 1-2, (2005)

[9]

Morrow M., White J., Moughan J., Factors predicting the use of breast-conserving treatment in stage I and II breast carcinoma, J Clin Oncol, 19, pp. 2254-2262, (2001)

[10]

Komoike Y., Akiyama F., Iino Y., Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer. Risk factors and impact on distant metastases, Cancer, 106, pp. 35-41, (2006)

← 1 2 3 4 5 6 7 8 9 →